Cyfuse Biomedical K.K. AI Stock Analysis
Want to see JP:4892 full AI Analyst Report?
Cyfuse Biomedical K.K. (4892) AI Stock Analysis
Cyfuse Biomedical K.K.
(TSE/TYO:4892)
The score is weighed down primarily by sustained unprofitability and persistent negative free cash flow, with only a moderately supportive balance sheet. Technical indicators also point to weak momentum with the price below key moving averages and negative MACD. Valuation provides limited support given losses (negative P/E) and no dividend yield data.
Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.19B
- Dividend Yield
- ―
- Average Volume (3M)
- 50.01K
- Price to Earnings (P/E)
- -6.3
- Beta (1Y)
- 0.46
- Revenue Growth
- 364.72%
- EPS Growth
- 18.43%
- Country
- Japan
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cyfuse Biomedical K.K. Business Overview & Revenue Model
Company Description
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic...
Cyfuse Biomedical K.K. Financial Statement Overview
Summary
Financial performance is weak: the company remains deeply unprofitable with very large operating and net losses relative to sales, and cash flow is consistently negative (continued cash burn). The balance sheet is only moderately supportive (manageable leverage), but rising debt and ongoing losses increase financing risk despite a strong 2025 revenue rebound.
Income Statement
14Very NegativeBalance Sheet
52NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 305.90M | 231.00M | 54.45M | 61.11M | 374.48M | 708.25M |
| Gross Profit | 145.27M | 78.40M | 1.56M | -378.00K | 223.93M | 568.20M |
| EBITDA | -743.38M | -792.68M | -860.12M | -659.31M | -370.81M | 89.07M |
| Net Income | -795.91M | -763.84M | -872.24M | -589.21M | -473.96M | 142.91M |
Balance Sheet | ||||||
| Total Assets | 3.93B | 4.27B | 3.52B | 4.21B | 4.82B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 3.39B | 3.73B | 3.05B | 3.87B | 4.44B | 2.41B |
| Total Debt | 1.23B | 1.31B | 852.80M | 913.00M | 857.79M | 569.06M |
| Total Liabilities | 1.30B | 1.51B | 975.60M | 1.01B | 1.05B | 746.12M |
| Stockholders Equity | 2.62B | 2.76B | 2.54B | 3.20B | 3.77B | 1.90B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -581.93M | -768.16M | -581.77M | -631.87M | 161.54M |
| Operating Cash Flow | 0 | -534.79M | -760.55M | -562.30M | -403.60M | 161.54M |
| Investing Cash Flow | 0 | -397.56M | -8.64M | -19.47M | -430.67M | -50.58M |
| Financing Cash Flow | 0 | 1.26B | -52.01M | 18.24M | 2.66B | 229.21M |
Cyfuse Biomedical K.K. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Negative. The current price of 514.00 is below the 20-day moving average (MA) of 556.20, below the 50-day MA of 601.64, and below the 200-day MA of 600.36, indicating a bearish trend. The MACD of -23.72 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 41.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4892.
Cyfuse Biomedical K.K. Peers Comparison
Overall Rating
JP:707980Outperform
JP:453946.5Neutral
JP:458243Neutral
JP:488343Neutral
JP:489242Neutral
JP:459739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | JPY 6.09B | 0.92 | ― | 3.75% | -8.78% | 0.01% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | JPY 5.47B | -11.50 | ― | 3.30% | 0.31% | -194.72% | |
| 43Neutral | JPY 5.95B | -0.65 | ― | ― | -30.58% | 6.93% | |
| 43Neutral | JPY 3.48B | -1.45 | ― | ― | ― | 25.34% | |
| 42Neutral | JPY 5.19B | -6.32 | ― | ― | 364.72% | 18.43% | |
| 39Underperform | JPY 6.82B | -8.22 | -53.06% | ― | 109.82% | 61.98% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4892 | Cyfuse Biomedical K.K. | 514.00 | -67.00 | -11.53% | |
| JP:4597 | Solasia Pharma KK | 25.00 | -8.00 | -24.24% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | 34.18 | 2.31% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 59.00 | -47.00 | -44.34% | |
| JP:4883 | Modalis Therapeutics Corporation | 30.00 | -37.00 | -55.22% | |
| JP:7079 | WDB coco Co., Ltd. | 2531.00 | 30.45 | 1.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
